ijerph-logo

Journal Browser

Journal Browser

Addicting Medications: Limited Therapeutics

A special issue of International Journal of Environmental Research and Public Health (ISSN 1660-4601). This special issue belongs to the section "Global Health".

Deadline for manuscript submissions: 30 September 2025 | Viewed by 1170

Special Issue Editors


E-Mail Website
Guest Editor
Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA 15213, USA
Interests: medicinal marijuana; medicinal marijuana legalization; opioid epidemic

Special Issue Information

Dear Colleagues,

Over the past several decades, addicting medications have become widespread and dangerous health problems within the United States. The opioid crisis, along with other drugs such as marijuana, stimulants, and psychedelics, are permeating and creating negative consequences on the population. Additionally, this rise in use is causing an unprecedented increase in mental health issues, legal issues, exacerbating already-present conditions, and causing other negative health effects, including death. This Special Issue will demonstrate how these drugs affect people negatively and their lack of efficacy, containing emerging research on how to help patients suffering from addiction diseases, the science of addiction itself, and the possibility that psychedelics are the next type of proposed medication leading to adverse public health consequences. The goal of this Issue is to showcase the negative effects that opioids, marijuana, stimulants, and psychedelics have on peoples’ health and on society due to addiction. This Special Issue will feature available studies that show how addictive medications have limited positive effects and predominantly negative effects when used chronically or even short-term, depending on the drug.

We encourage research about the following topics for submission:

  • What is addiction?
  • Amphetamines and differential diagnosis.
  • Psychedelic history.
  • Addictive use of medications, despite controlled environment.
  • The complicity of pharmaceutical companies and physicians with addicting medications.
  • Ease of diversion of addicting medications.
  • Health problems with psychedelics.
  • Why addicting medications are controlled substances.
  • Lack of research support.
  • Disrespect of addiction diseases.

Guest Editor

Dr. Norman S. Miller
Dr. Thersilla Oberbarnscheidt
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Environmental Research and Public Health is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2500 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • addiction
  • opioids
  • marijuana
  • psychedelics
  • medications

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

18 pages, 313 KiB  
Review
Psychedelics: Safety and Efficacy
by Norman Miller
Int. J. Environ. Res. Public Health 2025, 22(2), 134; https://doi.org/10.3390/ijerph22020134 - 21 Jan 2025
Viewed by 968
Abstract
Psychedelic research has experienced a renaissance in recent years, with many researchers exploring the possible therapeutic effects of these drugs. Medical institutions, universities, pharmaceutical companies, and governmental institutions alike have been showing an increase in support of this research, as shown through the [...] Read more.
Psychedelic research has experienced a renaissance in recent years, with many researchers exploring the possible therapeutic effects of these drugs. Medical institutions, universities, pharmaceutical companies, and governmental institutions alike have been showing an increase in support of this research, as shown through the recent establishment of various psychedelic research facilities across the United States. However, the safety and efficacy of psychedelic usage are not the focus of the existing research. Additionally, many of the studies on psychedelic use that have already been published lack the necessary scientific rigor required for studies of such medical importance. The current paper will discuss the issue of misleading information as well as poorly designed studies and what implications these have on the rescheduling of psychedelic drugs that are currently categorized as Schedule I. The current Schedule I status of psychedelics means that they are considered to have no legitimate medical value as well as a high potential for abuse. Furthermore, the current paper aims to discuss psychedelics while drawing awareness to the lack of the literature surrounding the safety and efficacy of psychedelics for medical use. This paper will also discuss the history of psychedelic use and abuse, the adverse effects of psychedelic use, and the role that personal and financial bias has within the psychedelic research field. Full article
(This article belongs to the Special Issue Addicting Medications: Limited Therapeutics)
Back to TopTop